Natera Inc., a leader in cell-free DNA and precision medicine, presented findings from a large-scale pan-cancer study of its Signatera Genome assay at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. The study, which involved 392 patients across five tumor types, demonstrated the assay's high performance with an overall pan-cancer sensitivity of 94% and specificity of 100%. Notably, the Signatera Genome assay detected cancer recurrence three months earlier on average than the Signatera Exome assay. The study also highlighted the assay's potential to guide adjuvant therapy decisions, showing improved outcomes for Signatera-positive patients who received therapy. Additionally, Signatera-negative patients exhibited excellent long-term outcomes, with a 100% distant relapse-free survival $(DRFS)$ at 12 months. The results emphasize the assay's capabilities in early detection and monitoring of cancer recurrence.